Answers are grounded in this paper and cite their sources.
Background: Medication for opioid use disorder (MOUD) is an evidence-based intervention that reduces overdose mortality and improves recovery outcomes. MOUD remains underutilized in many rural U.S. communities, where stigma toward opioid use disorder (OUD) and MOUD persists. Methods: We conducted in-depth semi-structured interviews with 33 members of community anti-drug coalitions across rural Appalachian Tennessee exploring MOUD perceptions. Using directed qualitative content analysis, we examined public stigma, structural stigma, label avoidance, and self-stigma. Results: Participants described four stigma domains: public stigma, structural stigma, label avoidance, and self-stigma. Public stigma reflected moralized interpretations of addiction, pharmaceutical distrust, and negative judgments in healthcare encounters. Structural accounts concerned law enforcement, employment, and treatment-system constraints. Label avoidance reflected anticipated judgment within recovery and coalition cultures privileging abstinence. Self-stigma was described as internalized shame and ambivalence among individuals considering or receiving MOUD. The analysis suggested relationships among these domains, with reported implications for treatment initiation, disclosure, and continued engagement. Conclusions: This study offers an interpretive account of “intervention stigma” across social and structural domains. These relationships do not establish causal or temporal pathways but identify perceived barriers to treatment in rural opioid response systems.
No takes yet. Share an insight, caveat, or question.
Kedia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: